Center-Authored Papers

Filters: Author is Ruebsamen-Schaeff, Helga  [Clear All Filters]
2014
Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Kriesel J, Fife K, Galitz L et al..  2014.  Helicase-primase inhibitor pritelivir for HSV-2 infection.. The New England journal of medicine. 370(3):201-10. Abstract
2016
Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, Fife K, Selke S, Huang M-L, Stobernack H-P et al..  2016.  Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.. JAMA. 316(23):2495-2503. Abstract
Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H, Stoelben S, Timmler B, Zimmermann H et al..  2016.  Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes.. Science translational medicine. 8(324):324ra15. Abstract
Edlefsen PT, Birkmann A, Huang M-L, Magaret CA, Kee JJ, Diem K, Goldner T, Timmler B, Stoelben S, Ruebsamen-Schaeff H et al..  2016.  No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.. The Journal of infectious diseases. 214(2):258-264. Abstract